Analyst Expectations for Rocket Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Rocket Pharmaceuticals (NASDAQ:RCKT) has received 5 bullish analyst ratings in the last quarter, with an average 12-month price target of $53.8, a decrease of 0.37% from the previous average price target of $54.00.
September 13, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rocket Pharmaceuticals has received 5 bullish analyst ratings in the last quarter, indicating positive sentiment towards the stock.
The bullish analyst ratings indicate a positive sentiment towards Rocket Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100